/
GeoVax Labs, Inc. ( GeoVax , us , we or the Company ) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax s primary near-term strategic development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and othe…
The business is unprofitable at the operating level (-869.34% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 37.1% YoY. Margins deteriorated 233.5pp alongside, both lines moving the wrong way.
Negative free cash flow of -$22M. The business is consuming cash, not generating it. Operating margin contracted 233.5pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$852K
▼ -37.1% YoY
Net Income (TTM)
-$21M
▲ +14.1% YoY
Op. Margin
-2523.43%
▼ -233.5pp YoY
ROIC
-511.57%
▲ +15.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$19M
▲ +12.9% YoY
Op. Cash Flow (TTM)
-$19M
▲ +13.0% YoY
Net Debt
-$877K
Net Cash Position
Cash & Equiv.
$1M
5Y CAGR: +6.4%
Continue Research